Has David Lawson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,056 in general payments to David Lawson, MD across 2 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Lawson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Lawson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Lawson, MD

Medical Oncology · Atlanta, GANPI 1528175205

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,000 of the $4,056 with a category attached, or 98.6%. Every reported general payment came from a single manufacturer, Partner Therapeutics, Inc.. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.

$4,056in general payments, 2019–2025

Across 2 payments — averaging $2028.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Partner Therapeutics, Inc.$4K

$391,608in research payments, 2019–2025

Across 52 payments — averaging $7530.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$241K
E.r. Squibb & Sons, L.L.C.$69K
Novartis$43K
Immunocore Limited$39K

What the payments were for

Consulting fees$4,00099%
Food & beverage$561%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Partner Therapeutics, Inc.	2	$4,056

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Leukine$4,000

How this compares

$4,056 in reported general payments places this provider in the 40th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$12,621

Medicare patients

Services billed

125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone Hcl	13	$116
Alprazolam	14	$11

Paid to pharmacies, not to this prescriber.

Other medical oncology in Atlanta

Nabil SabaAtlanta$225K
Suresh RamalingamAtlanta$75K
Jonathan KaufmanAtlanta$73K
Ragini KudchadkarAtlanta$69K
Nisha JosephAtlanta$50K
Eyal MeiriAtlanta$39K
Erin DunbarAtlanta$35K
Olumide GbolahanAtlanta$32K
Bradley CarthonAtlanta$31K
Joseph MaakaronAtlanta$29K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →